dr. A.J. van der Wekken

pulmonary oncologist

E-mail:
a.j.van.der.wekken umcg.nl

Research

  1. 2020
  2. van Veggel, B., Madeira R Santos, J. F. V., Hashemi, S. M. S., Paats, M. S., Monkhorst, K., Heideman, D. A. M., ... de Langen, A. J. (2020). Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer. Lung Cancer, 141, 9-13. https://doi.org/10.1016/j.lungcan.2019.12.013
  3. 2019
  4. 2018
  5. van Veggel, B., van der Wekken, A., Hashemi, S., Cornelissen, R., Monkhorst, K., Heideman, D., ... De Langen, J. (2018). Osimertinib treatment for patients with EGFR exon 20 insertion positive non-small cell lung cancer. Annals of Oncology, 29(Suppl.8), viii524-viii525. https://doi.org/10.1093/annonc/mdy292.072
  6. 2017
  7. 2016
  8. 2015
  9. Mellema, W. W., Masen-Poos, L., Smit, E. F., Hendriks, L. E. L., Aerts, J. G., Termeer, A., ... Dingemans, A-M. C. (2015). Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancer. Lung Cancer, 90(2), 249-254. https://doi.org/10.1016/j.lungcan.2015.09.012
  10. 2013
  11. 2012

ID: 35892471